Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epitope

This article was originally published in The Gray Sheet

Executive Summary

Plans to file a response within the next week to an FDA Form 483 report stemming from a three-week re-inspection of manufacturing plants for the company's OraSure oral specimen collection device. The report contained 17 observations, "most" of which pertain to problems with "machinery controls, control samples and sample sizes for quality control testing," and "minor changes to procedures, to the work instructions for those procedures and to record keeping for certain procedures" at the company's Beaverton and Troutdale, Oregon facilities, Epitope says. During the original inspection for the manufacturing plants in December and January, FDA issued a 483 with 57 observations ("The Gray Sheet" Feb. 28, p. 6). In May, the company reported that FDA had sent the firm a letter outlining the "final steps required for FDA action" on the firm's OraSure premarket approval application, which was submitted in April 1991

You may also be interested in...



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Stada Grabs GSK Brands In EU

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.

UsernamePublicRestriction

Register

MT002793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel